Especially when studying rare diseases and disorders such as RTT, mainly caused by de novo mutations of the MECP2 gene, for which obtaining high-risk samples is unrealistic (Marschik et al. 2018), retrospective procedures are still of great value. This evidence concerns the gene MECP2 and Rett syndrome.